JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
124.24
+0.39 (+0.31%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close123.85
Open123.78
Bid0.00 x 800
Ask0.00 x 800
Day's Range123.28 - 124.44
52 Week Range121.28 - 148.32
Volume5,433,919
Avg. Volume6,774,296
Market Cap333.23B
Beta0.59
PE Ratio (TTM)262.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target EstN/A
Trade prices are not sourced from all markets
  • Macy's, Johnson & Johnson and T. Rowe Price are the Yahoo Finance charts of the day.
    Yahoo Finance Video4 days ago

    Macy's, Johnson & Johnson and T. Rowe Price are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Macy's (M): Shares are up in early trade, around 7%.  The department store reported earnings and sales that beat analysts' expectations, citing a healthier inventory position after the holiday season that prompted the company to hike its outlook for the full year. Johnson & Johnson (JNJ): Shares up slightly at .26%.  The iconic brand is revamping its baby product line, putting more emphasis on natural ingredients. The company said it is confident that the move will reverse several years of declining sales of those products. T. Rowe Price (TROW): Shares rallying here, around 2.8%.  The stock was upgraded to "outperform" from "neutral" at Credit Suisse, which sites rising organic growth as well as better expense control at the investment firm. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Market Open: May 16, 2018
    CNBC Videos4 days ago

    Market Open: May 16, 2018

    CNBC brings you fast, accurate, and actionable business news and market updates.

  • Reuters36 minutes ago

    Congo to begin Ebola vaccinations on Monday

    H ealth workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said. Jessica Ilunga said 4,000 doses of vaccine were shipped on Saturday to the city of Mbandaka, which last week registered the first cases in an urban area since the latest flare-up of the disease was announced earlier this month. The outbreak is Congo's ninth since the disease made its first known appearance in the 1970s.

  • Reuters2 days ago

    Congo's Ebola not an international emergency, can be controlled -WHO

    GENEVA/KINSHASA, May 18 (Reuters) - The Ebola outbreak in Democratic Republic of Congo can be brought under control and is not an international public health emergency, experts advising the World Health Organization said on Friday. Earlier in the day the WHO had said the first confirmation of Ebola in Mbandaka, a city of about 1.5 million people, had prompted it to declare a "very high" public health risk to the country and a "high" risk to the region.

  • Eli Lilly’s Valuation on May 17
    Market Realist2 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks2 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Reuters2 days ago

    Johnson & Johnson scraps Alzheimer's trials on safety concerns

    Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease. Some trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said http://www.janssen.com/update-janssens-bace-inhibitor-program Janssen, a unit of Johnson and Johnson. Atabecestat belongs to a class of experimental Alzheimer's drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.

  • US birth rates hit record low and diaper, baby bottle companies are feeling the pinch
    CNBC2 days ago

    US birth rates hit record low and diaper, baby bottle companies are feeling the pinch

    As would-be parents push back parenthood and birth rates continue to decline companies that provide baby products are feeling the pinch.

  • Investopedia2 days ago

    Why J&J's Stock May Plunge 10%

    Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.

  • Benzinga3 days ago

    How To Get Quality In The Core

    Many exchange-traded funds that are viewed as “core” holdings are cap-weighted. Core funds that emphasize individual investment factors usually focus on growth or value with quality often left out of the ...

  • InvestorPlace3 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?
    Zacks3 days ago

    Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?

    Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist3 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Novartis Gains Ground, Completes the AveXis Acquisition
    Market Realist3 days ago

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist3 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • Why law school may be the next step for this recently retired health care CEO
    American City Business Journals3 days ago

    Why law school may be the next step for this recently retired health care CEO

    This is Clearwater Compliance founder Bob Chaput's third attempt at retirement.

  • 3 Growth Stocks to Buy and Hold for the Next 50 Years
    Motley Fool3 days ago

    3 Growth Stocks to Buy and Hold for the Next 50 Years

    Investors looking for growth opportunities they can hold for decades should consider these stocks.

  • Benzinga3 days ago

    Jim Cramer Shares His Thoughts On Johnson & Johnson, Nike And More

    Jim Cramer said on CNBC's "Mad Money Lightning Round"  he likes Johnson & Johnson (NYSE: JNJ ). Pure Storage Inc (NYSE: PSTG ) is a buy, thinks Cramer. He added that the company has a very smart ...

  • CNBC4 days ago

    Cramer's lightning round: Don't buy Apple suppliers right now

    Jim Cramer flies through his take on callers' favorite stocks, including a component maker.

  • Jobs alert: Johnson & Johnson Institute in Lake Nona ready to hire managers
    American City Business Journals4 days ago

    Jobs alert: Johnson & Johnson Institute in Lake Nona ready to hire managers

    The New Brunswick, N.J.-based Johnson & Johnson’s Human Performance Institute is looking for more people to join its Lake Nona team.

  • Macy's soars, Johnson & Johnson rallies, T. Rowe Price jumps
    Yahoo Finance4 days ago

    Macy's soars, Johnson & Johnson rallies, T. Rowe Price jumps

    Macy's, Johnson & Johnson and T. Rowe Price are the Yahoo Finance charts of the day.

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist4 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
    Zacks4 days ago

    Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

    Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

  • J&J CEO warns of 'unintended consequences' of Trump's drug-price reduction plan
    CNBC4 days ago

    J&J CEO warns of 'unintended consequences' of Trump's drug-price reduction plan

    "There are going to be changes in the pricing system" for prescription drugs, Johnson & Johnson chief Alex Gorsky acknowledges.

  • A Huge Decision Is on Tap for This Little Biotech Stock
    Motley Fool4 days ago

    A Huge Decision Is on Tap for This Little Biotech Stock

    A make-it or break-it determination is fast approaching for one tiny clinical-stage company.